|
|
||||||||
Volume 272, Number 48, Issue of November 28, 1997
pp. 30412-30420
(Received for publication, June 10, 1997, and in revised form, September 8, 1997)
From the Interferon- These results demonstrate that the coordinate activities of NFAT
and NF- Interferon- Cloning of the p50 and p65 NF- Here, we provide evidence that cooperation between NFAT and NF- Fresh human peripheral blood T lymphocytes
were incubated in RPMI 1640 medium containing 2% fetal calf serum, 2 mM glutamine, and 100 units/ml penicillin/streptomycin. For
growth of the human T cell line, Jurkat, the concentration of fetal
calf serum was 10%. For the different treatments (as stated in the
text), we used the following concentrations: phorbol 12-myristate
13-acetate (PMA), 10 ng/ml; phytohemagglutinin (PHA), 1 µg/ml; and
cyclosporin A (CsA), 100 ng/ml.
For nuclear extract preparation, the cells
were cultured for 4 h in the presence or absence of the indicated
treatments, and nuclear proteins were prepared as follows. The cellular
pellet was resuspended in 10-20 times its volume in buffer A (lysis
buffer) containing 50 mM KCl, 0.5% Nonidet P-40, 25 mM Hepes (pH 7.8), 1 mM phenylmethylsulfonyl
fluoride, 10 µg/ml leupeptin, 20 µg of aprotinin, 100 µM DTT and was subsequently incubated 5 min in ice. Cells
were collected by centrifugation at 2000 rpm, and the supernatant was
decanted. The nuclei were washed in buffer A without Nonidet P-40,
collected at 2000 rpm and resuspended in buffer B (extraction buffer)
containing 500 mM KCl, 25 mM Hepes pH (7.8),
10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 20 µg/ml aprotinin, and 100 µM DTT
for 5 min in ice. The samples were subsequently frozen and thawed
(twice) utilizing dry ice and a 37 °C water bath, rotated 20 min at
4 °C, and centrifuged at 14,000 rpm for 20 min. The clear
supernatant was collected, and the proteins were dialyzed for 4 h
against buffer C (dialysis buffer) containing 50 mM KCl, 25 mM Hepes (pH 7.8), 10% glycerol, 1 mM
phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 20 µg/ml
aprotinin, and 100 µM DTT. The nuclear proteins were
incubated with radiolabeled DNA probes in a 20-µl reaction mixture
containing 20 mM Tris (pH 7.5), 60 mM KCl, 2 mM EDTA, 0.5 mM DTT, 1 µg of poly(dI-dC), and
4% Ficoll. Nucleoprotein complexes were resolved by electrophoresis on
5% nondenaturing polyacrylamide gels in 0.5 × Tris borate/EDTA
buffer at 12 V/cm for 2 h at room temperature. Dried gels were
exposed to Kodak XAR-5 film at The CD4+ human T lymphoblastoid
cell line Jurkat (clone J. LEI) was transiently transfected by the
DEAE-dextran method (35). The cells were harvested 48 h later and
assayed as described previously for CAT (36) and The p50 expression vector was
constructed as follows: the HindIII-NotI fragment
of a CMV construct expressing the p105 precursor of p50 NF-
[View Larger Version of this Image (14K GIF file)]
[View Larger Version of this Image (35K GIF file)]
Sequence
analysis of the IFN- Table I.
Sequence homology between the IFN- Based on previous reports indicating the promoter region (nucleotide
[View Larger Version of this Image (36K GIF file)]
Table II.
Mutagenesis study of the C3-3P binding site
Interaction of NF-
B and NFAT with the Interferon-
Promoter*
§¶,
,
,
,
,
Laboratory of Experimental Immunology,
Biological Carcinogenesis Development Program,
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
(IFN-
) is a pleiotropic
lymphokine whose production is restricted to activated T cells and NK
cells. Along with other cytokines, IFN-
gene expression is inhibited
by the immunosuppressant cyclosporin A. We have previously identified
an intronic enhancer region (C3) of the IFN-
gene that binds the
NF-
B protein c-Rel and that shows partial DNA sequence homology with
the cyclosporin A-sensitive NFAT binding site and the 3
-half of the
NF-
B consensus site. Sequence analysis of the IFN-
promoter
revealed the presence of two additional C3-related elements (C3-1P and
C3-3P). In addition, an NF-
B site (IFN-
B) was identified
within the promoter region. Based on this observation, we have analyzed
the potential role of NF-
B and NFAT family members in regulating
IFN-
transcription. Electrophoretic mobility shift assay analysis
demonstrated that after T cell activation, the p50 and p65 NF-
B
subunits bind specifically to the newly identified IFN-
B and
C3-related sites. In addition, we identified the NFAT proteins as a
component of the inducible complexes that bind to the C3-3P site.
Site-directed mutagenesis and transfection studies demonstrate that
calcineurin-inducible transcriptional factors enhance the
transcriptional activity of the IFN-
promoter through the
cyclosporin-sensitive C3-3P site, whereas NF-
B proteins functionally
interact with the C3-related sites. In addition, when located
downstream to the
-galactosidase gene driven by the IFN-
promoter, the intronic C3 site worked in concert with both the IFN-
B and the C3-3P site to enhance gene transcription.
B proteins are involved in the molecular mechanisms controlling IFN-
gene transcription.
(IFN-
)1 is an important
immunoregulatory protein responsible for several immunological effects
(1), including induction of the Fc receptor, major histocompatibility
complex class I and II expression (2), regulation of cytokine gene expression (IL-1, IL-6, and tumor necrosis factor) (3), and promotion
of activation of immune effector cells, including B lymphocytes and
monocytes. IFN-
production in vivo is largely restricted
to activated T cells and large granular lymphocytes (1, 4-6). Although
the immunological properties of IFN-
have been widely investigated
(for reviews see Refs. 1, 7, and 8), the molecular mechanisms by which
IFN-
gene transcription is regulated have been shown to involve a
wide variety of transcription factors (9-18). Interestingly, the
IFN-
gene belongs to a group of lymphokines whose expression is
inhibited by the immunosuppressant cyclosporin A (1, 19), and in
activated T cells, its transcription parallels that of other lymphokine
genes (e.g. IL-2) whose promoter activity is enhanced by
both NF-
B and NFAT proteins (19). This laboratory has identified a
c-Rel binding site (C3) (20), located in the first intron of the human
IFN-
gene, that may have a role in the control of IFN-
transcription. This site, which lies in a previously described IFN-
enhancer region (9), has a strong homology with the 3
-half of NF-
B
consensus sequence and the NFAT binding sites. In this regard, whereas
NF-
B is a ubiquitous factor controlling the transcription of a
number of cytokines (21-25), its role in the IFN-
gene expression
has been suggested (20) despite the lack of identification of canonical
NF-
B binding sites within its genomic DNA. Similarly with NF-
B, a
role for the cyclosporin A-sensitive NFAT proteins as activators of
IFN-
gene transcription has also been proposed (19, 26, 27) and a
potential NFAT binding site in the IFN-
promoter has been identified (15).
B subunits (21, 22, 23) revealed a
significant homology between the amino-terminal portion of these
proteins, which contains the binding and dimerization domain (Rel
homology domain), with the Rel family of oncoproteins and with the
Drosophila developmental morphogen dorsal (22, 24, 25).
Interestingly, the cloning of members of the NFAT family of
transcriptional factors demonstrated structural similarity between the
Rel homology domain, the carboxyl terminus of the NFATc, and the middle
portion of NFATp proteins (28-30). These findings were also paralleled
by the observation that NFAT and NF-
B proteins may recognize similar
DNA sequences (31, 32). As NF-
B and NFAT transcriptional factors
play a pivotal role in coordinating induction of many cytokine genes in
activated T cells, the identification of additional C3-related sites
located in the IFN-
promoter prompted us to investigate the possible role of NF-
B and NFAT proteins in enhancing IFN-
gene
transcription.
B
proteins induces maximal transcription of the IFN-
gene, resulting
from a synergistic activity between promoter and intronic enhancers.
Cell Culture
70 °C with intensifying screens.
Oligonucleotides were synthesized on a DNA synthesizer (Applied
Biosystems, model 392) and were end-labeled using Klenow enzyme and
[
-32P]dCTP; approximately 1 ng of labeled DNA was used
in a standard electrophoretic mobility shift assay (EMSA) reaction. The
following antisera were used in supershift analysis: 1141, raised
against a peptide containing residues 2-16 of human p50 (33); 1226, raised against a peptide containing the carboxyl-terminal 14 residues of human p65 (33); anti-NFATc antiserum (7A6) (30); anti-NFATc antiserum (796) recognizes all members of the NFAT family (34).
-galactosidase (13)
activities.
B subunit
(37) was subcloned into a K-RSPA vector (36). The
XbaI-XbaI fragment (amino acids 505-966) was
deleted to obtain the RSVp50 (amino acids 1-504) expression vector.
The RSV-based p65 and RSV control expression vectors were kindly
provided by Dr. Gary Nabel (38). To prepare the C3-3PCAT
((C3-3P)3TKCAT) construct, three copies of the IFN-
C3-3P sequence 3 (GGA GGT ACA AAA AAA TTT CCA GTC C) were subcloned upstream to the
thymidine kinase (TK) promoter in the pBLCAT2 parental vector (39). The constitutively active mutant of calcineurin expression vector was
kindly provided by Dr. Neil A. Clipstone and Dr. Gerard Crabtree (27).
The wild type
796 to +64 IFN-
promoter DNA and the different mutants (m1, m2, m3, m4, m5, m6, and m7) represented in Fig. 6 (panel A) were generated by polymerase chain reaction
amplification from a promoterless LacZ plasmid, pEQ3, containing the
human IFN-
promoter region nucleotide
2700 to + 64 (13). The
amplified products were then subcloned in the
HindIII-BglII restriction sites of the pEQ3
parental vector. To prepare the IFN-
796 to
761 TKGal construct
(plasmid B, Fig. 5), the IFN-
promoter region (nucleotides
796 to
761) was subcloned upstream to the thymidine kinase promoter in the SmaI-HindIII restriction
sites of the TKGal parental vector (plasmid A, Fig. 5). This vector was
derived by subcloning the HindIII-XhoI fragment
of the pBLCAT2 plasmid, containing the thymidine kinase promoter, in
the HindIII-XhoI restriction sites of the pEQ3
plasmid.
Fig. 6.
Panel A, schematic representation of the
IFN-
promoter mutants transfected into the Jurkat T cell line.
Panel B, site-directed mutagenesis of the IFN-
B;
C3-1P and C3-3P sites inhibit the maximal transcriptional activity of
the IFN-
promoter nucleotides
796 to +64. Six µg of the
indicated plasmids were transfected as indicated. Fold of induction
refers to the level of
-galactosidase detected in unstimulated
Jurkat cells transfected with the WT construct (to which a value of 1.0 was assigned). Results are expressed as the average (X ± S.E.) of four different experiments.
Fig. 5.
Functional analysis of the IFN-
DNA
promoter region nucleotides
796 to
761. Jurkat T cells were
transfected with either the (IFN-
796 to
761)TKGal construct
(plasmid B) or the TKGal parental vector (plasmid A). Four µg of
plasmids A or B were co-transfected with 4 µg of either the p50, p65,
or parental CMV vectors as indicated. Fold of induction refers to the
level of
-galactosidase activity detected in unstimulated Jurkat
cells transfected with construct A together with the empty expression vector CMV (to which a value of 1.0 was assigned). Transfection efficiencies were normalized for the amount of plasmid uptake using a
CAT reporter vector as a control, and the results are expressed as the
average (X ± S.E.) of four different experiments.
NF-
B Family Members Together with the NFATc Protein Are
Components of the PMA/PHA-inducible C3-3P Complexes
promoter region of the human gene has
identified two DNA sequences, C3-1P and C3-3P, highly homologous to the
c-Rel binding site (C3) present in the first intron of this gene (20).
As shown in Table I, these C3-related elements also share sequence similarity with NFAT and NF-
B binding sites. In addition, a putative IFN-
NF-
B binding site was also identified in the IFN-
promoter. These observations prompted us to
investigate the potential interaction of NFAT and NF-
B proteins with
these DNA elements.
B and IFN-
C3-related sites
with NF-
B (51, 52) and NFAT (19, 32, 50, 54) consensus sequences
Consensus p50 NF-
B subunitG
G G G A T Y C C C
Consensus p65 NF-
B subunitG G G
R N T T T C C
Consensus c-Rel
N
G G N N W T T C C
IFN-
B site (
786 to
776)G G G G A G T T C C
(R.O.)
hNFAT (IL-2)
T A T G A A A C A G T T T T T
C C
(R.O.)
mNFAT (IL-2)
T A T G A A A C A
A A T T T T C C
(R.O.)
NF(p) (IL-4) (
78 to
69)G A A A A T T T C C
C3 1st intron
(459-470)
T A T G A A T T T T C C
C3-1P (
772
to
763)A A A A T A T T C C
(R.O.)
C3-3P
(
278 to
268)A A A A A T T T C C
284 to
260) of the IFN-
gene, which contains the C3-3P element
(AAAATTTCC), as a regulatory DNA sequence necessary for its inducible
transcriptional activity (11-15) and on the sequence homology (Table
I), we performed EMSA analysis utilizing a 32P-labeled
C3-3P containing oligonucleotide (Fig. 1,
panels A-C). In the presence of nuclear extract from
untreated T lymphocytes, only a weak complex formation was observed
(panel B, lane 1). However, PMA/PHA treatment enhanced the
protein complex binding to this DNA element (lane 2). Fig. 1
(panel A) shows a competition study of the C3-3P DNA-protein
complex. Binding of the complexes to the DNA probe was
sequence-specific since it was blocked by excess of unlabeled C3-3P
oligonucleotide (lane 2) but not by excess of nonspecific
unlabeled oligonucleotide (lane 8). Since we previously
described the C3 site as a c-Rel binding site (20), we also used an
oligonucleotide containing the IL-2R
NF-
B binding site as an
unlabeled competitor. This oligonucleotide (lane 3) was able
to compete the C3-3P complex, suggesting a possible involvement of Rel
family members in the assembly of the C3-3P complexes. As shown in
Table I and as reported elsewhere (15) while this work was in progress,
the C3-3P site displays sequence similarity also with NFAT binding
sites. We therefore used as competitors cold oligonucleotides
containing the human IL-4 NF(P) (panel A, lane 4) and the
human distal IL-2 NFAT (panel C, lane 3) sites. Both these
oligonucleotides were able to compete the C3-3P DNA-protein complex,
although with different affinities, suggesting that NFAT proteins may
also be part of it. These results are in agreement with the recent
observation that NF-
B and NFAT proteins may bind identical DNA
sequences (31, 32). Next, mutagenesis analysis of the C3-3P site
(AAAAATTTCC) was carried out by using as cold competitors (panel
A, lanes 5-7) three oligonucleotides (C3-3PmA, C3-3PmB, and
C3-3PmC) containing different mutations (Table
II) within the C3-3P sequence. As shown,
only oligonucleotide C3-3PmA (AAAAATTTTT) (lane 5) was
unable to compete the formation of the C3-3P complex. These results
indicated that the two cytosines located in the 3
-half of the C3-3P
site are essential for its binding activity. In support of this
observation, when oligonucleotide C3-3PmA was used as
32P-labeled probe in the presence of a nuclear extract from
PMA/PHA activated fresh human T lymphocytes, no binding activity was
observed (lane 9).
Fig. 1.
Gel shift analysis of the C3-3P DNA-protein
complex. Panel A, lanes 1-9, human T lymphocytes
treated with PMA/PHA for 4 h; lanes 2-8, competition
with 200 ng of unlabeled C3-3P, human IL-2R
B site, IL-4 NF(p),
C3-3P mA, C3-3P mB, C3-3P mC, and nonspecific competitor (SP-1),
respectively. In lane 9 a 32P-labeled C3-3P mA
oligonucleotide was used as probe. Panel B, lane 1,
untreated T lymphocytes; lanes 2-5, PMA/PHA-treated T cells; lane 3, anti-p50 (antiserum 1141); lane 4,
anti-p65 (antiserum 1226); lane 5, nonspecific antiserum.
Panel C, lanes 2-4, competition with 200 ng of unlabeled
C3-3P, distal IL-2 NFAT, and nonspecific oligonucleotide, respectively;
lane 5, anti-NFATc (antiserum 796); lane 6,
anti-NFATc (antiserum 7A6); lane 7, nonspecific
antiserum.
Competition of the C3-3P DNAprotein complex
C3-3P wild
type
5
-GGTACAAAAAATTTCCAGT-3
+
C3-3PmA
5
-GGTACAAAAAATTTttAGT-3
C3-3PmB
5
-GGTACAAAAggTTTCCAGT-3
+
C3-3PmC
5
-GGTACAggAAATTTCCAGT-3
+
To characterize the composition of the C3-3P complex, we performed
supershift analysis. Since the NF-
B and NFAT oligonucleotides were
effective competitors for the C3-3P complex formation, we utilized
antisera raised against peptides of the p50, p65 NF-
B subunits
(panel B) and the NFATc protein (panel C). As
visible in panel B, both the anti-p50 (lane 3)
and anti-p65 (lane 4) antisera were able to supershift the
middle portion of the C3-3P DNA-protein complex, whereas a nonspecific
antiserum (lane 5) had no effect. Also, anti-NFAT antisera
(panel C) were able to compete or supershift, respectively
(lanes 5 and 6), a considerable part of the
complex but not the NF-
B heterodimer. When we tested an anti-c-Rel
antiserum, only a minor fraction of the C3-3P complexes were
supershifted (data not shown). These results identified both NF-
B
and NFAT proteins as the inducible binding factors interacting with the C3-3P site.
B p65 and a Constitutively Active Mutant of Calcineurin
Functionally Activate the IFN-
C3-3P Enhancer Activity
Our
binding studies demonstrated the interaction of NF-
B and NFAT
proteins with the C3-3P site. To define the functional significance of
these DNA-protein complexes, we subcloned three copies of the C3-3P
site upstream of the thymidine kinase (TK) promoter in the pBLCAT2
parental vector. As shown in Fig. 2, this construct was co-transfected into the human lymphoma T cell line, Jurkat, with either expression vectors for p65 NF-
B, p50 NF-
B, or
a constitutively active mutant of the calcineurin phosphatase (27).
C3-3P
site in the Jurkat T cell line. Transient transfections were
performed using the (C3-3P)3TKCAT2 reporter construct. Four µg of the
CAT constructs were co-transfected with 4 µg of expression vectors as
indicated. Fold of induction refers to the level of CAT activity
detected in unstimulated Jurkat cells transfected with the
(C3-3P)3TKCAT2 construct together with the empty expression vector CMV
(to which a value of 1.0 was assigned). Transfection efficiencies were
normalized for the amount of plasmid uptake using a
-galactosidase
reporter vector as a control and are expressed as the average
(X ± S.E.) of four different experiments.
[View Larger Version of this Image (34K GIF file)]
Co-transfection of either the p65 NF-
B or the calcineurin expression
vector resulted in a significant transactivation of the C3-3P-CAT
activity over the activities observed in the presence of either the CMV
or pBJ5 parental vectors. In untreated cells the C3-3PCAT construct was
activated about 28-fold by p65 and 15-fold by calcineurin, whereas the
p50 expression vector and the parental pRSPA and pBJ5 empty vectors did
not significantly affect reporter activity. In cells treated with PMA
or PMA/PHA, however, the effects of the p65 and calcineurin expression
vectors were further increased. As expected, cyclosporin A prevented
the calcineurin-induced increase in promoter activity but only slightly inhibited the up-regulation due to p65. The CAT activity of the pBLCAT2
parental vector, used as a control, was not significantly affected by
these treatments (data not shown). Thus, we have identified a site
(C3-3P) within the IFN-
promoter region that is highly responsive to
NF-
B p65 and to a factor, presumably NFATc, that is activated by
calcineurin.
B and C3-1P Sites Have NF-
B Binding
Activity
As the possible presence of additional NF-
B binding
sites suggests an NF-
B dependent activation of IFN-
gene
transcription, we next characterized the nuclear protein binding
activity of the IFN-
B and C3-1P sites. In EMSA analysis, we used
as a 32P-labeled probe, an oligonucleotide spanning the
IFN-
promoter region (nucleotides
796 to
761)
(Table III) and containing both the
IFN-
B and C3-1P elements (Fig. 3).
As shown in Fig. 3, panel B, incubation of this probe with a
nuclear extract from PMA/PHA-treated fresh human T lymphocytes resulted
in the formation of an inducible DNA-protein complex (lane
2). While in the presence of nuclear extract from untreated T
lymphocytes, only a weak binding was observed (lane 1). As
shown in Fig. 3, panel A, the DNA-protein complex formation
was specific since competition with a cold nonspecific oligonucleotide
did not abolish the binding (lane 12), and the cold wild
type oligonucleotide containing the IFN-
promoter region nucleotides
796 to
761 was able to specifically block the complex formation
(lane 7).
|
||||||||||||||||||||||||||||||||||||
promoter
DNA nucleotides
796 to
761. Panel A, lanes 1-12, T
cells treated with PMA/PHA for 4 h; lanes 2-12,
competition with 200 ng of unlabeled C3-1P, C3-1P M2, IFN-
B,
IFN-
B M1, IFN-
B M4, IFN-
promoter DNA nucleotides
796 to
761, M4, M1, M2, human IL-2R
B site, and nonspecific
competitor, respectively. Panel B, lane 1, untreated T
cells; lanes 2-5, PMA/PHA; lane 3, anti-p50
(antiserum 1141); lane 4, anti-p65 (antiserum 1226);
lane 5, nonspecific antiserum. Panel C, lanes
1-7, PMA/PHA; lanes 2-4, competition with 200 ng of
unlabeled IFN-
796 to
761, distal IL-2 NFAT and nonspecific oligonucleotide, respectively; lane 5, anti-NFATc (antiserum
796); lane 6, anti-NFATc (antiserum 7A6); lane 7,
nonspecific antiserum.
[View Larger Version of this Image (36K GIF file)]
To investigate the binding activity of the C3-1P site, a cold
oligonucleotide containing the C3-1P sequence (Table III) was used as
competitor (Fig. 3, panel A, lane 2). This oligonucleotide could efficiently, but not completely, compete the DNA-protein formation, whereas a mutant of the C3-1P oligonucleotide, C3-1P M2
(lane 3), did not. We also tested the capability of a cold oligonucleotide containing the IFN-
B site to act as a
competitor. This oligonucleotide (lane 4) completely blocked
the formation of the DNA-protein complex, while two different mutants,
the IFN-
B M1 (lane 5) and IFN-
B M4 (lane
6) oligonucleotides, were unable to block the complex formation.
To evaluate better the individual contribution of the IFN-
B and
C3-1P sites to this binding activity, we generated additional mutations
within the wild type oligonucleotide (nucleotide
796 to
761). In
agreement with results seen in lanes 2-5, the mutants M4
and M1 (lanes 8 and 9) could efficiently, but not
totally, block the DNA-protein complex formation, whereas the mutant M2
(lane 10) completely abolished the binding. A cold
oligonucleotide containing the IL-2 R
NF-
B site also completely
blocked the formation of the complex (lane 11). The results
of this study are summarized in Table III and indicate that the
sequence
796 to
761 of the IFN-
promoter interacts with protein
complexes whose binding is specifically competed by cold NF-
B
oligonucleotides.
Based on this observation, we performed supershift analysis to
investigate the possible interaction of NF-
B proteins with this
IFN-
promoter region (Fig. 3, panel B). This complex was completely shifted by anti-p50 and anti-p65 antisera (lanes
3 and 4), whereas a nonspecific antiserum (lane
5) did not affect complex formation. Due to the observation that
NF-
B and NFAT proteins may bind similar DNA sequences (31, 32), we
also investigated whether NFAT protein may share affinity for the
oligonucleotide containing the IFN-
region
796 to
761. As shown
in Fig. 3, panel C, no competition was observed with a cold
oligonucleotide containing the distal IL-2NFAT site (lane
3), and NFAT antisera (lanes 5 and 6) were
not able to supershift or block DNA-protein complex formation.
As both the cold IFN-
B and C3-1P oligonucleotides were able to
compete the NF-
B binding to the IFN-
WT oligonucleotide, we also
performed EMSA analysis utilizing these oligonucleotides (Table III) as
32P-labeled oligonucleotide probes. Cold competition and
supershift analysis (Fig. 4) confirmed
that both the IFN-
B and the C3-1P sites specifically bind the
inducible p50/p65 NF-
B heterodimer. In particular, the C3-1P
oligonucleotide (Fig. 4, panels C and D) showed
formation of multiple DNA-protein complexes. Interestingly, our data
identify the slower C3-1P migrating complex of region a, supershifted
either by anti-p50 or anti-p65 antisera (panel C, lanes 7 and 8), as the p50/p65 NF-
B heterodimer. In addition, a
faster migrating C3-1P DNA-protein complex (region a) was completely eliminated by the anti-p50 antiserum,but not by the anti-p65 antiserum, suggesting that this complex represents the p50 NF-
B homodimer. A
third C3-1P complex (region b) was also observed, but the protein composition of this complex was not characterized. These results confirmed the binding of NF-
B proteins but not NFAT proteins to both
the IFN-
B and C3-1P sites. The formation of additional DNA-protein complexes that were detected using the short C3-1P oligonucleotide may indicate its partial affinity for other protein complexes.
B and C3-1P promoter sites. 32P-Labeled
oligonucleotides containing the IFN-
B (panels A and B) or the C3-1P (panels C and D) site
were used as indicated in the presence of a nuclear extract from fresh
human T lymphocytes. Panel A, lane 1, untreated T cells;
lanes 2-8, T cells treated with PMA/PHA for 4 h;
lanes 3-5, competition with 200 ng of unlabeled IFN-
B, human IL-2R
B site, and nonspecific competitor,
respectively; lane 6, anti-p50 (antiserum 1141); lane
7, anti-p65 (antiserum 1226); lane 8, nonspecific
antiserum. Panel B, lanes 1-7, T cells treated with PMA/PHA
for 4 h; lanes 2-4, competition with 200 ng of
unlabeled IFN-
B, distal IL-2 NFAT, and nonspecific
oligonucleotide, respectively; lane 5, anti-NFATc (antiserum
796); lane 6, anti-NFATc (antiserum 7A6); lane 7,
nonspecific antiserum. Panel C, lane 1 untreated T cells.
Lanes 2-9, T cells treated with PMA/PHA for 4 h;
lanes 3-5, competition with 200 ng of unlabeled C3-1P,
human IL-2R
B site, and nonspecific oligonucleotide,
respectively; lane 6, no antiserum; lane 7,
anti-p50 (antiserum 1141); lane 8, anti-p65 (antiserum
1226); lane 9, nonspecific antiserum. Panel D, lanes
1-7, T cells treated with PMA/PHA for 4 h; lanes
2-4, competition with 200 ng of unlabeled C3-1P, distal IL-2
NFAT, and nonspecific oligonucleotide, respectively; lane
5, anti-NFATc (antiserum 796); lane 6, anti-NFATc
(antiserum 7A6); lane 7, nonspecific antiserum.
[View Larger Version of this Image (54K GIF file)]
The p65 Subunit Is a Functional Transactivator of the IFN-
Promoter Region
796 to
761
To investigate the functional
significance of NF-
B protein binding to the IFN-
B-C3-1P
tandem promoter element, we subcloned one copy of this region
(nucleotides
796 to
761) upstream of the TK promoter in the TK
-galactosidase parental vector. This construct (plasmid B) was then
transfected in the Jurkat T cell line. As shown in Fig.
5, both PMA/PHA treatment and
co-transfection with a p65 NF-
B expression vector were able to
induce
-galactosidase activity in the presence of the IFN-
B-C3-1P tandem promoter element. Combination of these treatments
resulted in a even stronger transactivation. In contrast a p50 NF-
B
expression vector was not able to induce
-galactosidase activity.
These results provide evidence for a functional interaction of NF-
B
with the IFN-
B-C3-1P tandem promoter element.
B, C3-1P, and C3-3P Sites Are Regulatory DNA
Elements Required for Maximal Transcriptional Activity of the IFN-
Promoter
Although both the C3-3P site and the IFN-
B-C3-1P
tandem promoter element showed significant enhancer activity when
subcloned upstream of a heterologous promoter, we investigated their
functional role in the context of the native IFN-
promoter. Based on
our mutagenesis studies (Tables II and III) we generated a number of mutations within the IFN-
promoter region (nucleotide
796 to +64)
that selectively abolished the binding activities of either the C3-3P,
C3-1P, or IFN-
B sites (Fig. 6,
panel A). The mutant constructs were subcloned upstream to
the
-galactosidase reporter gene in the parental vector pEQ3 (13).
As shown in Fig. 6 (panel B), all the mutated constructs
displayed lower activity than the wild type construct, demonstrating
the functional role of the mutated DNA elements IFN-
B, C3-1P,
and C3-3P in the induction of the human IFN-
promoter
transcriptional activity. Furthermore, the combination of mutations m2
and m5 (plasmid m6) or m5 and m4 (plasmid m7) slightly increased the
inhibitory effect observed with the single mutations.
Promoter through the C3-3P DNA Element
The fact that the
C3-3PCAT activity can be induced by either NF-
B or NFAT proteins
raised the question of which proteins regulate the C3-3P enhancer
activity in the context of the intact IFN-
promoter. To provide
insight into this issue, we compared the CsA sensitivity of the wild
type and C3-3P mutant (m5) constructs (Fig.
7; panel A). In addition, we
co-transfected both reporter constructs with either the calcineurin
phosphatase (panel A) or the p65 NF-
B (panel
B) expression vector. As shown in Fig. 7, the calcineurin
expression vector was able to enhance the
-galactosidase activity of
the WT construct in both untreated and PMA/PHA-treated cells, and CsA
co-treatment resulted in the suppression of the calcineurin-induced
activities. The calcineurin vector also potentiated to a minor extent
the activity of the m5 mutant; while in the presence of CsA the
PMA/PHA-induced activities of the WT and m5 constructs were equivalent.
While co-transfection of the p65 NF-
B expression vector (panel
B) resulted in a lower activity of the m5 mutant in untreated and
PMA/PHA-treated cells, in comparison with the WT construct, no
appreciable differences were observed (as fold of induction) between
these reporter constructs. As in the presence of the calcineurin
expression vector, we observed a higher fold of induction with the WT
construct in comparison with the m5 mutant construct. These results
suggest that within the native IFN-
promoter the C3-3P enhancer
activity is mainly activated by calcineurin-inducible transcriptional
factors consistent with a previous report (15), suggesting that the
NF-
B-mediated induction of the IFN-
promoter activity acts mainly
through the IFN-
B-C3-1P tandem promoter element.
B (panel B) on the
-galactosidase activity expressed by the WT and m5 reporter
constructs. Fold of induction refers to the level of
-galactosidase activity detected in unstimulated Jurkat cells transfected with the WT construct together with the empty expression vectors CMV or pBJ5, respectively (to which a value of 1.0 was assigned). Four µg of the indicated plasmids were transfected as
indicated into the Jurkat T cell line. Results are expressed as the
average (X ± S.E.) of three different experiments.
[View Larger Version of this Image (25K GIF file)]
The Intronic c-Rel Binding Site (C3) Enhances IFN-
Promoter
Activity
To define better the relative significance of the NFAT
and NF-
B binding sites identified within the IFN-
promoter and to investigate possible functional cooperation with the intronic C3
enhancer region, one or two copies of the previously identified c-Rel
intronic site C3 (20) were linked downstream of the
-galactosidase gene in the WT, m2, m4, and m5 constructs. Fig.
8 represents the
-galactosidase
activity expressed by the constructs containing one or two copies,
respectively, of the intronic C3 site over the activities expressed by
the parental constructs. Values were normalized with the
PMA/PHA-induced activity expressed by the WT construct, to which a
value of 1.0 was assigned. Upon PMA/PHA treatment, the WT construct
containing either one or two copies of the intronic C3 site displayed a
strong increase of the
-galactosidase activity. Noteworthy,
mutations affecting either the C3-3P (m5) or the IFN-
B (m4)
binding activities resulted in a lack of synergism with the C3
enhancer, whereas loss of C3-1P binding (m2) only partially decreased
it. Thus, both the C3-3P and IFN-
B binding sites appear to
cooperate with the intronic C3 enhancer to promote optimal activity of
the IFN-
promoter.
promoter transcriptional activity. Fold of induction
refers to the respective levels of PMA/PHA-induced
-galactosidase
activity expressed in Jurkat cells by the WT, m2, m4, or m5 reporter
constructs. Values were normalized with the
-galactosidase activity
expressed by the WT construct to which a value of 1.0 was assigned.
Four µg of the indicated plasmids were transfected into the Jurkat T
cell line. Results are expressed as the average (X ± S.E.)
of three different experiments. C3 represents one copy of
the intronic C3 site; 2C3 represents two copies of the
intronic C3 site.
[View Larger Version of this Image (25K GIF file)]
A number of reports have investigated the molecular mechanisms
regulating the IFN-
gene transcription. A consensus GATA motif and
an NFIL-2-like element have been identified within the CsA-sensitive proximal promoter (nucleotide
108 to
40) of the human IFN-
gene
(13), and the binding of CREB/ATF, AP-1, and octamer families of
transcription factors to this region of the promoter has been reported
(16). This region of the promoter has been subdivided into two
elements, a proximal element (
70 to
47) and a distal element (
98
to
72) (13), and the importance of these elements in regulating
IFN-
gene expression has been elegantly demonstrated through the use
of transgenic mice by Aune and co-workers (17). In this report, the
proximal and distal elements were shown to direct transcription in
memory but not naive T cells in response to stimulation through the T
cell receptor. Additionally, the CD4+ but not the CD8+ population of T
cells expressed proximal activity. Thus these elements seem to be
essential for IFN-
expression in these cell types. More recently,
Barbulescu and co-workers (18) have used in vivo
footprinting to identify a new site (
196 to
183) that binds a
PMA/PHA-inducible complex in Jurkat T cells and purified CD45RO
peripheral blood T cells. These investigators have proposed a model
where induction of the AP-1 proteins to this region of the promoter is
involved in the increased transcription of the IFN-
gene in response
to stimulation. Although the promoter sites described in these recent
publications are required for the transcription of the IFN-
gene, it
is also clear that additional negative (40) and positive (11)
regulatory elements play a role in the control of IFN-
mRNA
initiation and that optimal conditions for IFN-
gene expression
likely require the cooperation between different regulatory elements.
We have previously identified a novel c-Rel binding site (C3) (20) that
is located within an IFN-
intronic enhancer region and that shares
sequence homology with either NFAT or NF-
B binding sites (Table I).
In this report, we have characterized the binding activity and
functional properties of two newly identified C3-related sites (C3-1P
and C3-3P) and a novel NF-
B (IFN-
B) site located in the
promoter region and provide evidence for a functional cooperation
between these newly identified enhancers and the intronic c-Rel site
C3. Our data demonstrate the presence, within the human IFN-
promoter, of multiple targets for the NF-
B binding activity. The
importance of these sites in regulating IFN-
expression likely
depends upon the specific extracellular signal that triggers IFN-
expression. We have previously demonstrated (41) that IL-2 but not
IL-12 induces the nuclear appearance in the nucleus of NF-
B proteins in a human NK cell line, and the interaction of the NF-
B proteins within the regions of the IFN-
promoter described here may serve to
enhance the transcription initiation of the gene. Although the specific
biochemical pathways triggering the activation of IFN-
expression
have not been completely defined, a recent report (42) has implicated
Raf kinase as an important intracellular mediator for the induction of
IFN-
expression through the T cell receptor in human CD4+ Th 1 cells. Raf kinase has been demonstrated to be important for AP-1
activation (43), and Kanno and Siebenlist (44) have also reported a
functional synergy between Raf and calcineurin that results in NF-
B
activation. Thus the activation of numerous transcription factors,
including NF-
B, may be critical for achieving a maximal activation
of IFN-
transcription. The activation may also be dependent upon
cell type because in addition to T cells and NK cells, murine
peritoneal macrophages (45) and mast cells (46), human eosinophils
(47), human keratinocytes (48), and primary human B cells (49) have all
been recently reported to express IFN-
mRNA.
In addition to binding NF-
B p50/p65, the C3-3P site described in
this article also binds the NFATc protein, emphasizing its similarity
with the IL-4 NF(p) site (Table I), which also binds NF-
B and NFAT
proteins (32). This site exactly corresponds to a region previously
mapped by Brown and co-workers (11) that responds to mitogen
stimulation. In addition, while our work was in progress, Campbell and
co-workers (15) reported the same region as a potential NFAT binding
site. In our experiments, both anti-NF-
B and NFAT antisera were able
to supershift co-migrating but discernible portions of the C3-3P
DNA-protein complexes, suggesting that NF-
B and NFAT proteins
independently bind the C3-3P site. The ability of both NF-
B and NFAT
proteins to bind the same site is not surprising given the recent
discovery that the NFATc phosphoprotein is a distant relative of the
Rel/NF-
B proteins (28, 30). In addition, a previous report has also
described the binding of an NFAT-like factor to a classic
B site
(31). By analogy with the IL-4 NF(P) site (32), the common capability
of NF-
B and NFAT proteins to functionally interact with the C3-3P
site highlight the possibility that NF-
B and NFAT proteins, although expressed through independent signaling pathways, may exercise their
transcriptional activity through common enhancer elements. These
results add IFN-
to the family of genes that are regulated, at least
in part, by the NF-
B and NFAT families of transcription factors.
We have previously reported (20) that a bacterially expressed p50
NF-
B protein could bind to the intronic C3 oligonucleotide. However,
we could not detect binding of the p50 homodimer at the C3-3P site,
thus supporting its selective binding by the p50/p65 heterodimer. Thus,
although it is known that the NF-
B p50 homodimer binds
preferentially the 5
-end Gs containing
B sites (51, 52), thus
making possible the binding of the p50 homodimer to the 5
-end of the
single C3-1P oligonucleotide, it is possible that occupancy of the
IFN-
B site by the p50/p65 heterodimer may impair the access of
the p50 NF-
B homodimer at the 5
-end of the C3-1P site. The
observation that p50 NF-
B does not significantly affect the activity
of the C3-3P, IFN-
B-C3-1P DNA tandem element as well as the
IFN-
promoter activity (not shown) is in line with the observation
that p50 is devoid of an activation domain and that p65 is necessary
for transcriptional activity (25).
Understanding the role of the first intron in regulating IFN-
gene
expression is of special interest as Xu and co-workers (53) have
identified STAT binding sites very near the intronic C3 element. As the
enhanced promoter activity observed when the C3 site was placed
downstream of the reporter gene was eliminated when either the IFN-
B or the C3-3P binding activity were selectively abolished by point
mutation, optimal transcription of the IFN-
gene results from
synergism between promoter and intronic enhancers. Thus it may be
possible that cooperation between STATs and NF-
B occurs, further
enhancing IFN-
transcription. This hypothesis will require more
detailed mutational analysis of these sites in the context of the human
IFN-
genomic DNA structure.
In conclusion, this work provides evidence for the functional
interaction between the NF-
B and NFAT family of DNA-binding proteins
with regulatory regions of the IFN-
promoter and defines the C3-3P
site and the IFN-
B-C3-1P tandem element as enhancer elements
required for maximal IFN-
gene transcription. Our data establish the
IFN-
gene as an additional transcriptional model where the NF-
B
and NFAT DNA-protein complexes play a role in enhancing transcriptional
activity.
This article is dedicated to the life and memory of Linda Dorman,
who died unexpectedly on June 22, 1997.
,
interferon-
; NF-
B, nuclear factor-
B; NFAT, nuclear factor of
activated T cells; EMSA, electrophoretic mobility shift assay; PMA,
phorbol 12-myristate 13-acetate; CsA, cyclosporin A, CAT,
chloramphenicol acetyltransferase; DTT, dithiothreitol; IL,
interleukin; PHA, phytohemagglutinin; RSV, Rous sarcoma virus; CMV,
cytomegalovirus; TK, thymidine kinase; WT, wild type.
We thank Earl W. Bere and Anna Mason for
their technical support, Drs. John Ortaldo and Dan Longo for critical
reading of the manuscript, and Joyce Vincent and Susan Charbonneau for
secretarial and editorial assistance. We appreciate the gift of the p65
NF-
B subunit expression vector from Dr. Gary Nabel, Howard Hughes
Medical Institute, University of Michigan Medical Center, Ann Arbor,
MI; Dr. Alain Israel, Unité de Biologie Moleculaire de
l'Expression Genique, Institute Pasteur, Paris, France, for the p105
NF-
B expression vector; and Dr. Neil A. Clipstone and Dr. Gerald R. Crabtree, Beckman Center for Molecular and Genetic Medicine, Stanford University School of Medicine, Stanford, CA, for the constitutively active mutant of calcineurin expression vector and the anti-NFATc antiserum 7A6.